NDAORALTABLET1 Generic Approved
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
25
Data completeness
3/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLAVIX (clopidogrel) is an oral small-molecule P2Y12 receptor antagonist approved in November 1997 for reducing the rate of myocardial infarction and stroke in patients with acute coronary syndromes (ACS), including unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and acute ST-elevation myocardial infarction (STEMI). As a platelet aggregation inhibitor, clopidogrel works by blocking the P2Y12 adenosine diphosphate receptor on platelets, preventing thrombotic events. PLAVIX is a foundational antiplatelet therapy widely used in secondary prevention and acute coronary syndrome management.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention
Started Apr 2026
100 enrolled
Chronic Coronary Syndrome
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Started Nov 2025
96 enrolled
Drug Drug Interaction (DDI)
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Started Mar 2023
11,086 enrolled
Coronary Artery Disease
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
Started May 2022
12 enrolled
End-Stage Renal DiseaseKidney Failure, Chronic
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
Started Dec 2020
1,000 enrolled
Coronary Artery DiseaseMyocardial IschemiaMyocardial Infarction+1 more
Worked on PLAVIX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.